Medication info
Empagliflozin and Sitagliptin and Metformin Hydrochloride Extended-Release Tablets 25/100/1000 mg

Empagliflozin and Sitagliptin and Metformin Hydrochloride Extended-Release Tablets 25/100/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›25mg / 1 tabletSitagliptin Phosphate Hydrate›128.5mg / 1 tabletMetformin Hydrochloride with Colloidal Anhydrous Silica›1010mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Round, biconvex, yellow film-coated extended-release tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202501537 · Approved 2025.06.20 · Insurance code 671808030

Summary

Main use
Improvement of blood glucose control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the recommended dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily doses of the individual components: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal in the evening. If the dose of metformin hydrochloride needs adjustment, increase the dose gradually. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine is empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current dose of metformin hydrochloride or a therapeutically similar dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching to this medicine from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine should be the patient's existing dose of each component. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, treatment with this medicine must be discontinued immediately.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of blood glucose control in adults with type 2 diabetes

View approved original text

This medication is administered to enhance blood glucose control in adult patients with type 2 diabetes as an adjunct to diet and exercise. The combination of empagliflozin, sitagliptin, and metformin effectively manages blood glucose levels to assist in diabetes treatment.

How to take

Adult dose

For antidiabetic therapy, the recommended dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum daily doses of the individual components: empagliflozin 25 mg, sitagliptin 100 mg, and extended-release metformin hydrochloride 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal in the evening. If the dose of metformin hydrochloride needs adjustment, increase the dose gradually. Patients taking this medicine as 25/100/1000 mg or 10/100/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/50/750 mg or 5/50/750 mg extended-release tablets should take 2 tablets once daily. If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine is empagliflozin 10 mg, sitagliptin 100 mg, and the patient's current dose of metformin hydrochloride or a therapeutically similar dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. For patients switching to this medicine from combination therapy with empagliflozin, sitagliptin, and metformin hydrochloride, the dose of this medicine should be the patient's existing dose of each component. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and <60mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and <60mL/min/1.73m2], this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, if it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 ml/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 ml/min/1.73m2, treatment with this medicine must be discontinued immediately.

Precautions

This medication contains three components: sitagliptin, empagliflozin, and metformin hydrochloride. Firstly, the sitagliptin component may cause severe allergic reactions, albeit rarely. Such reactions can appear within 3 months after starting the medication; if symptoms such as skin rash, difficulty breathing, or swelling of the face or throat occur, you should discontinue the medication immediately and seek medical attention. Additionally, it may cause acute pancreatitis, an inflammation of the pancreas, so symptoms like abdominal pain, nausea, or vomiting should be observed closely during treatment. The metformin hydrochloride component may cause lactic acidosis, which is a rare but very serious metabolic disorder. Symptoms can include difficulty breathing, muscle pain, weakness, and abdominal pain. It is particularly advisable for patients with impaired kidney function, liver impairment, severe dehydration, or ongoing infections to avoid this medication. This drug should not be administered to patients with type 1 diabetes, acute or chronic kidney disorders, acute heart failure, myocardial infarction, or patients scheduled for surgery with severe infections. Regular kidney function tests should be conducted during treatment, particularly in elderly patients and those with slightly impaired kidney function who may require more frequent monitoring. There is a risk of hypoglycemia associated with this medication; therefore, caution should be taken for patients on insulin or sulfonylureas to observe symptoms of low blood sugar and respond promptly if they appear. Moreover, this medication may lead to dehydration or low blood pressure, so intake should be temporarily discontinued and a physician consulted if symptoms such as diarrhea, vomiting, or fever lead to fluid loss. Increased occurrences of genital infections or urinary tract infections may occur, so prompt treatment is necessary if related symptoms appear. Caution is advised while driving or operating machinery due to the risk of hypoglycemia, and it is recommended to avoid alcohol consumption during treatment. The tablets should be swallowed whole and not chewed or crushed; it is normal for the tablet coating to appear in the stool. It is essential to consult healthcare professionals immediately if any unusual symptoms or discomfort occur during treatment.

Side effects

  • Severe allergic reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • dyspepsia
  • abdominal pain
  • hyperglycemia
Show 249 more
  • poorly controlled diabetes
  • genital itching
  • vulvar pruritus
  • vaginal infection
  • weight loss
  • thirst
  • rash
  • vulvodynia
  • vaginitis
  • balanitis
  • other genital infections
  • urinary tract infections
  • perineal necrosis
  • constipation
  • urticaria
  • angioedema
  • increased urination
  • dysuria
  • interstitial nephritis
  • fever
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • headache
  • cerebral infarction
  • intracranial aneurysm
  • vascular stent stenosis
  • vascular stent thrombosis
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • ureteral stones
  • acute kidney injury
  • cervical inflammation
  • diabetes
  • hyponatremia
  • diabetic foot
  • back pain
  • glaucoma
  • pathological myopia
  • retinal detachment
  • retinal vein occlusion
  • macular retinal detachment
  • limb injuries
  • road traffic accidents
  • splenic injury
  • sternal fracture
  • angina
  • Prinzmetal angina
  • coronary artery disease
  • deep vein thrombosis
  • benign neoplasm of the ampulla of Vater
  • benign ovarian tumor
  • bladder cancer
  • gastric cancer
  • pancreatic carcinoma
  • rectal cancer
  • thyroid cancer
  • uterine leiomyoma
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • anxiety
  • depression
  • sleep disorders
  • otalgia
  • position-related dizziness
  • dizziness
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • dyspepsia
  • gastritis
  • dizziness
  • chest discomfort
  • chest pain
  • weakness
  • weight loss
  • vulvar pruritus
  • genital itching
  • dyslipidemia
  • hyperglycemia
  • back pain
  • diabetic retinopathy
  • dry eyes
  • cough
  • dyspnea
  • unstable angina
  • hypertension
  • insomnia
  • taste disturbance
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
  • pruritus
  • urticaria
  • rash
  • severe arthralgia with disability
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • severe arthralgia
  • vesicular pemphigoid
  • acute renal failure
  • severe hypoglycemia
  • severe delayed hypoglycemia
  • decreased fluid volume
  • blood glucose ≤ 70 mg/dL
  • hypoglycemia requiring treatment
  • vesicles or abrasions
  • dry mouth
  • abdominal distension
  • anal bleeding
  • chronic gastritis
  • ischemic colitis
  • enteritis
  • bloating
  • gastric polyps
  • gingival swelling
  • passage of bloody stools
  • hemorrhoids
  • colon bleeding
  • pancreatic cysts
  • rectal pain
  • dental pain
  • upper respiratory tract infections
  • bronchitis
  • soft tissue infections
  • chronic sinusitis
  • gastroenteritis
  • Helicobacter infection
  • periodontitis
  • appendiceal abscess
  • appendicitis
  • chronic tonsillitis
  • conjunctivitis
  • influenza
  • laryngitis
  • tinea corporis
  • dental abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • nasopharyngitis
  • position-related dizziness
  • sensory impairment
  • perceptual disturbances
  • amnestic syndrome
  • carotid stenosis
  • diabetic neuropathy
  • facial paralysis
  • memory disturbances
  • neuralgia
  • Parkinsonism
  • polyneuropathy
  • sensory dysfunction
  • drowsiness
  • central nervous system-origin dizziness
  • facial paralysis
  • drowsiness
  • fatigue
  • peripheral edema
  • facial swelling
  • peripheral swelling
  • chills
  • strange sensations
  • swelling
  • pain
  • pain at the puncture site
  • ECG abnormalities
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine erythrocytes
  • hematuria
  • overactive bladder
  • kidney masses
  • urinary retention
  • urinary pain
  • abnormal urination
  • benign prostatic hyperplasia
  • erectile dysfunction
  • atrophic vaginitis
  • cervical dysplasia
  • vaginal discharge
  • hypoglycemia
  • decreased appetite
  • somnolence
  • vitamin D deficiency
  • dermoid cysts
  • seborrheic dermatitis
  • atopic dermatitis
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • pain from fractures
  • muscle weakness
  • musculoskeletal pain
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal erosion
  • macular fibrosis
  • ocular discomfort
  • conjunctival hyperemia
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • epistaxis
  • asthma
  • age-related dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • skin lacerations
  • contusions
  • rib fractures
  • concussion
  • corneal abrasion
  • falls
  • hand fractures
  • ligamentous injury syndrome
  • open eye injuries
  • pelvic fractures
  • arteriosclerosis
  • diabetic vascular diseases
  • peripheral artery occlusive disease

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The appropriate storage temperature is between 1 to 30 degrees Celsius (33.8 to 86 degrees Fahrenheit). Avoid extremely hot or cold locations and keep it in a cool place away from direct sunlight.

Appearance and packaging

Appearance

Round, biconvex, yellow film-coated extended-release tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.